Literature DB >> 2204725

A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology.

F Clavel1, J M Orenstein.   

Abstract

A deletion of 30 bases was created in the noncoding region of the human immunodeficiency virus type 1 genome that extends between the 5' splice donor and the start of the gag gene. Viral particles produced after transfection of this mutant provirus had a normal protein pattern but a reduced RNA content. The infectivity of the mutant virus was also markedly reduced but not completely abolished. Electron-microscopic examination of the mutant virions revealed major abnormalities of the nucleoid structure, mostly related to the dense material characteristic of mature particles, suggesting that the presence of RNA is essential to the normal structure of the nucleoid.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204725      PMCID: PMC248025     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Recombination between a defective retrovirus and homologous sequences in host DNA: reversion by patch repair.

Authors:  P Schwartzberg; J Colicelli; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

2.  Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire.

Authors:  S Benn; R Rutledge; T Folks; J Gold; L Baker; J McCormick; P Feorino; P Piot; T Quinn; M Martin
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus.

Authors:  R L Willey; R A Rutledge; S Dias; T Folks; T Theodore; C E Buckler; M A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

5.  Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs.

Authors:  R Mann; D Baltimore
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

6.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

7.  Transfer of defective avian tumor virus genomes by a Rous sarcoma virus RNA packaging mutant.

Authors:  M Linial
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

8.  Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus.

Authors:  T Folks; S Benn; A Rabson; T Theodore; M D Hoggan; M Martin; M Lightfoote; K Sell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

9.  Rapid reversion of a deletion mutation in Moloney murine leukemia virus by recombination with a closely related endogenous provirus.

Authors:  S C Martinelli; S P Goff
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

10.  Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.

Authors:  H R Gelderblom; E H Hausmann; M Ozel; G Pauli; M A Koch
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

View more
  102 in total

1.  The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.

Authors:  B Berkhout; J L van Wamel
Journal:  RNA       Date:  2000-02       Impact factor: 4.942

2.  Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Role of RNA in facilitating Gag/Gag-Pol interaction.

Authors:  Ahmad Khorchid; Rabih Halwani; Mark A Wainberg; Lawrence Kleiman
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA.

Authors:  Rodney S Russell; Jing Hu; Véronique Bériault; Andrew J Mouland; Michael Laughrea; Lawrence Kleiman; Mark A Wainberg; Chen Liang
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Mutational interference mapping experiment (MIME) for studying RNA structure and function.

Authors:  Redmond P Smyth; Laurence Despons; Gong Huili; Serena Bernacchi; Marcel Hijnen; Johnson Mak; Fabrice Jossinet; Li Weixi; Jean-Christophe Paillart; Max von Kleist; Roland Marquet
Journal:  Nat Methods       Date:  2015-08-03       Impact factor: 28.547

7.  Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

8.  Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA.

Authors:  A Cimarelli; S Sandin; S Höglund; J Luban
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

9.  An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Authors:  E Vicenzi; D S Dimitrov; A Engelman; T S Migone; D F Purcell; J Leonard; G Englund; M A Martin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.